The core of your canine protocol
Vanguard DAPP contains attenuated strains of CDV, CAV2, CPiV and CPV. The high-titer, low-passage CPV virus in Vanguard DAPP is highly immunogenic and capable of stimulating active immunity in the presence of maternal antibodies. This product does not contain CPV type 2c. Cross protection against CPV type 2c was demonstrated in vaccinated puppies challenged 5 weeks following second vaccination.
CAV2 cross-immunizes against CAV1 to help protect dogs against infectious canine hepatitis without producing post-vaccination side effects, including uveitis and corneal opacity, sometimes associated with CAV1 vaccines.